Partruvix (pamiparib) / BeOne Medicines - LARVOL DELTA

Safety and tolerability of PARP inhibitors in cancer patients: a network meta-analysis of randomized controlled trials. (PubMed, BMC Cancer) - "In our study, pamiparib demonstrates the most favorable safety profile among evaluated PARP inhibitors relatively, while senaparib might be associated with a higher incidence of AEs. PARPi plus anti-angiogenic drug or chemotherapy might cause the most occurrence of AEs relatively. Therefore, on the basis of balancing efficacy and safety, selecting optimal PARPi and formulating tailored combination therapy for individual patients is necessary."

Journal • Retrospective data • Review • Oncology

Advancements in the manufacturing routes for the synthesis of marketed PARP inhibitors. (PubMed, RSC Adv) - "To date, seven PARP inhibitors have received marketing approval, namely, olaparib, rucaparib, niraparib, talazoparib, fuzuloparib, pamiparib and senaparib, in various countries. These modern approaches integrate key transformations, such as amide bond formation, C-H activation, carbopalladation, heterocycle construction, and stereocontrolled cyclisation, enabling improved efficiency and scalability. In parallel, the incorporation of green chemistry principles, particularly in one of the manufacturing routes of olaparib, has led to more sustainable process development."

Journal • Review • Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor

BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov) - P3 | N=404 | Completed | Sponsor: BeOne Medicines | Active, not recruiting ➔ Completed

Trial completion • Oncology • Solid Tumor

Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801). (PubMed, AJNR Am J Neuroradiol) - P1/2 | "TGR changes were significantly associated with survival outcomes, suggesting that growth stabilization may be an important metric for assessing treatment benefit in IDH-mutant gliomas."

Journal • P2 data • Brain Cancer • Glioma • Oncology • Solid Tumor

Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors (clinicaltrials.gov) - P1 | N=44 | Completed | Sponsor: M.D. Anderson Cancer Center | Active, not recruiting ➔ Completed

Trial completion • Oncology • Solid Tumor • ARID1A • BRCA1 • BRCA2 • CHEK1 • CHEK2 • EMSY • PARP1 • PTEN • RAD50

Study of Pamiparib in Newly Diagnosed and rGBM (clinicaltrials.gov) - P1 | N=50 | Completed | Sponsor: Nader Sanai | Active, not recruiting ➔ Completed | Trial completion date: Jul 2026 ➔ May 2025

Trial completion • Trial completion date • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Efficacy and Safety of Pamiparib Monotherapy in Recurrent Ovarian Cancer After Prior PARPi Exposure: A Prospective, Open-Label, Single-Arm, Phase II Study. (PubMed, J Obstet Gynaecol Res) - "Pamiparib monotherapy preliminarily showed limited efficacy and acceptable safety profiles in heavily pretreated rOC after prior PARPi exposure. The results suggested that single-agent pamiparib retreatment may not be an effective treatment for this patient population; further investigation of combining PARPi with agents with different mechanisms may be warranted."

Journal • Monotherapy • P2 data • Oncology • Ovarian Cancer • Solid Tumor

Prospective, single-arm, multicenter phase II clinical study of pamiparib combined with TC regimen and bevacizumab in neoadjuvant therapy for untreated advanced ovarian cancer (ChiCTR) - P2 | N=38 | Completed | Sponsor: Fujian Cancer Hospital; Fujian Cancer Hospital | Not yet recruiting ➔ Completed

Trial completion • Oncology • Ovarian Cancer • Solid Tumor

Translational research to facilitate development of novel therapeutic combinations of letrozole for the treatment of glioblastoma (AACR 2024) - "It synergistically enhances the efficacy of the DNA alkylating agent temozolomide, one of the few approved chemotherapeutics for GBM, against patient-derived GBM cells...Employing patient-derived G43, G75 and JHH-136 GBM lines we assessed the influence of PARP inhibitors (olaparib, pamiparib, veliparib and niraparib) in combination with LTZ on cell viability and neurosphere growth...Overall, these results provide a strong foundation for pursuing further development of combination therapy of GBM with LTZ and PARP inhibitors. A careful assessment of the clinical efficacy and safety profile of these agents will further guide shortlisting combination of LTZ for pre-clinical and clinical development."

Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • BRCA2

Pamiparib-induced replication stress augments the efficacy of temozolomide in GBM PDX models (AACR 2025) - "In conclusion, pamiparib enhances TMZ efficacy in a subset of primary GBM. While further in vivo validation is needed, TLS deficiency may be a key determinant of pamiparib-mediated sensitization."

Clinical • Glioblastoma • Oncology • MGMT • MRE11A

A phase 0/2 'trigger' trial of pamiparib or olaparib plus radiotherapy in patients with newly-diagnosed or recurrent glioblastoma (AACR 2024) - "Pamiparib achieved pharmacologically-relevant concentrations in Gd-nonenhancing GBM tissue and suppressed induction of PAR levels ex vivo post-radiation. The majority of newly-diagnosed patients with MGMT-unmethylated GBM and recurrent GBM patients advanced to therapeutic dosing in this trial, and pamiparib was generally well-tolerated in these patients."

Clinical • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • MGMT

BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov) - P3 | N=404 | Active, not recruiting | Sponsor: BeOne Medicines | Enrolling by invitation ➔ Active, not recruiting

Enrollment closed • Oncology • Solid Tumor

BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov) - P3 | N=430 | Enrolling by invitation | Sponsor: BeOne Medicines | Trial completion date: Dec 2026 ➔ Jul 2026 | Trial primary completion date: Dec 2026 ➔ Jul 2026

Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Neoadjuvant Pamiparib in Newly Diagnosed Advanced Ovarian Cancer: A Single-Arm, Prospective Phase II Trial (SGO 2026) - No abstract available

Clinical • Metastases • P2 data • Oncology • Ovarian Cancer • Solid Tumor

Denosumab Combined With PARP Inhibitors and Chemoradiotherapy for Treating Triple Negative Breast Cancer With Bone Metastasis: A Case Report. (PubMed, Cancer Rep (Hoboken)) - "This case suggests that the combination of denosumab with PARP inhibitors and chemoradiotherapy may provide a potential therapeutic strategy for TNBC patients with bone metastasis. Further studies are warranted to validate the efficacy and safety of this combined treatment approach."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HRD

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer (clinicaltrials.gov) - P1/2 | N=29 | Completed | Sponsor: Sun Yat-sen University | Recruiting ➔ Completed | Trial completion date: Aug 2025 ➔ Jan 2026

Platinum resistant • Trial completion • Trial completion date • Carcinosarcoma • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Sarcoma • Solid Tumor

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: University of Chicago | Trial completion date: Jan 2026 ➔ Jan 2028 | Trial primary completion date: Jan 2026 ➔ Jan 2028

Trial completion date • Trial primary completion date • Head and Neck Cancer • Oncology • Oropharyngeal Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • PD-1 • PD-L1

A Phase II Single-Arm, Open-Label Trial of Pamiparib in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients with Deleterious Germline or Somatic BRCA1/2 Alterations or Homologous Recombination Deficiency (HRD) (EAU 2026) - No abstract available

Clinical • Metastases • P2 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • BRCA1 • BRCA2 • HRD

Efficacy and safety of PARP inhibitors in metastatic breast cancer patients with homologous recombination repair pathway gene mutations: a retrospective multicenter real-world study. (PubMed, Ther Adv Med Oncol) - "In total, 62 MBC patients treated with olaparib (N = 55), talazoparib (N = 4), pamiparib (N = 2), and fluzoparib (N = 1) were enrolled. Hematologic toxicity was the most common grade ⩾3 AEs. PARPis showed promising PFS and tolerable toxicity in the real-world treatment of Chinese MBC patients with HRR-related gene mutations."

Journal • Real-world evidence • Retrospective data • Breast Cancer • Hematological Disorders • Leukopenia • Oncology • Solid Tumor • BRCA1 • BRCA2 • HRD

BGB-290-302: Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer (clinicaltrials.gov) - P3 | N=224 | Active, not recruiting | Sponsor: BeiGene | Trial completion date: Jun 2027 ➔ Jan 2027 | Trial primary completion date: Jun 2026 ➔ Dec 2025

Platinum sensitive • Trial completion date • Trial primary completion date • Oncology • Ovarian Cancer • Solid Tumor

Neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: an open-label, single-arm, phase 2 study. (PubMed, Prostate Cancer Prostatic Dis) - "Neoadjuvant pamiparib plus abiraterone and ADT demonstrated efficacy, safety, and potential QoL benefits in HRPCa/VHRPCa."

Journal • P2 data • Dyslipidemia • Genito-urinary Cancer • Hematological Disorders • Hypertriglyceridemia • Oncology • Prostate Cancer • Solid Tumor • Urinary Incontinence • Urology • HRD

PNOC017: BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (clinicaltrials.gov) - P1 | N=78 | Active, not recruiting | Sponsor: University of California, San Francisco | Recruiting ➔ Active, not recruiting

Enrollment closed • Brain Cancer • Glioblastoma • Glioma • High Grade Glioma • Oncology • Solid Tumor • IDH1 • IDH2

Drug combination discovery assisted by AI and untargeted metabolomics: pamiparib and anlotinib synergistic potentiation for ovarian cancer treatment. (PubMed, Front Pharmacol) - "In vivo, significant downregulation of p-PI3K, p-Akt, Bcl-2, and HIF1-α, and upregulation of BAX protein expression confirmed that the mechanism of action of combination therapy is related to PI3K/Akt pathway. The combination of PAM and ANL was more effective than monotherapy for treating ovarian cancer and holds potential to become a new therapeutic approach for ovarian cancer."

IO biomarker • Journal • Oncology • Ovarian Cancer • Solid Tumor • ANXA5 • BAX • BCL2 • HIF1A

Broad-spectrum anti-influenza activity of the NMPA-approved drug Pamiparib is uncovered by virtual docking to the evolutionarily conserved domain of IAV-M2 protein. (PubMed, Bioorg Med Chem) - "In addition, pamiparib suppresses effectively viral infection in vivo. Ultimately, this study verifies that antiviral drugs designed to target the evolutionarily conserved regions of the influenza virus M2 protein indeed possess broad-spectrum antiviral activity across different strains."

Journal • Infectious Disease • Influenza • Respiratory Diseases

Poly (ADP-ribose) polymerase (PARP) inhibitors approved for the treatment of cancer. (PubMed, Pharmacol Res) - "The FDA has approved four PARP inhibitors (olaparib, rucaparib, niraparib, and talazoparib) for the treatment of ovarian, breast, prostate, and pancreatic cancer...The Chinese NMPA has approved three PARP antagonists (fuzuloparib, pamiparib, senaparib) for the treatment of ovarian cancer. All seven of these drugs are orally bioavailable and fall within the criteria of Lipinski's rule of five. Drug resistance develops in most PARP-inhibitor-treated cancer patients within one or two years."

Journal • Review • Breast Cancer • Genito-urinary Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Solid Tumor • BRCA1 • BRCA2 • HRD